ASH 2024: Cilta-Cel Achieves Sustained MRD Negativity in Patients With Multiple Myeloma

by | Dec 26, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.
Read More

Submit a Comment